Journal Article

Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells

Ichinohasama, Ryo, Katsushima, Hiroki, Fujishima, Fumiyoshi, Fukuhara, Noriko, Harigae, Hideo, Nakamura, Yasuhiro, Sasano, Hironobu

2021

Overview

Background It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining for CD30. Therefore, we devised a notation that we termed proportion of immunoreactivity/expression for FCM (PRIME-F notation), based on the cellular proportion showing different antigen-antibody reactivity. Methods We retrospectively compiled 211 cases of T-cell lymphoma, assessed via FCM, from major hospitals in Miyagi Prefecture from January 2012 to January 2019, and compared 52 of these cases with the immunohistochemical immunoreactive (IR) pattern of CD30 (PRIME-I notation). The PRIME-F notation was divided into five levels: notations starting with “-” followed by 3, 2, and 1 “>” correspond to level-I, level-II, or level-III; notations starting with “(dim)+” correspond to level-IV; and those starting with “+” or “(bright)+” correspond to level-V. Results The 52 cases of PRIME-F notation with “+” included 16 cases of peripheral T-cell lymphoma (PTCL/NOS), 3 of follicular T-cell lymphoma (FTL), 3 of angioimmunoblastic T-cell lymphoma (AITL), 6 of extranodal NK/T-cell lymphoma/nasal type (ENKL), 18 of adult T-cell lymphoma (ATL), and 6 cases of anaplastic large cell lymphoma (ALCL). Eight of the 52 cases were immunohistochemically CD30-negative. In the PRIME-F level-I to III group (excluding false-positive cases), 21.7% (5 out of 23 cases) were < 10% positive for CD30 upon immunohistochemistry (IHC). Contrarily, in the level-IV & -V group, no CD30 positivity rate of < 10% upon IHC was found (0%) ( p  = 0.0497). In level-IV, 42.9% of cases presented a CD30 negative rate  >  1/3 upon IHC, while in level-V, only 7.1% (one out of 14 cases) did. The CD30 negative rate tended to be low ( p  = 0.0877) in level-V. Conclusions To our knowledge, this is the first report describing the correspondence between FCM and immunohistochemistry findings for CD30 through newly proposed notations. The PRIME-F and PRIME-I notations for CD30 showed a minor positive correlation. The PRIME notation is considered universally applicable to antibodies, and notations of both FCM and IHC show great potential for big data.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Anaplastic large-cell lymphoma / Antigens / Automation / Biomedical and Life Sciences / Biomedicine / Biopsy / Bone Marrow - pathology / Cancer Research / CD30 / CD30 antigen / Comparative analysis / Diagnosis / Flow cytometry / Flow Cytometry - statistics & numerical data / Health Promotion and Disease Prevention / Humans / Immunohistochemistry / Immunohistochemistry - statistics & numerical data / Immunology / Ki-1 Antigen - analysis / Ki-1 Antigen - metabolism / Lymphocytes T / Lymphoma / Lymphoma, T-Cell - blood / Lymphoma, T-Cell - diagnosis / Lymphoma, T-Cell - pathology / Lymphomas / Malignant lymphoma / Medicine/Public Health / Normal distribution / Notation / Oncology / Retrospective Studies / Risk factors / Surgical Oncology / T-cell lymphoma